MXPA05013596A - Antagonistas de hormona concentradora de melanina para el tratamiento de obesidad. - Google Patents
Antagonistas de hormona concentradora de melanina para el tratamiento de obesidad.Info
- Publication number
- MXPA05013596A MXPA05013596A MXPA05013596A MXPA05013596A MXPA05013596A MX PA05013596 A MXPA05013596 A MX PA05013596A MX PA05013596 A MXPA05013596 A MX PA05013596A MX PA05013596 A MXPA05013596 A MX PA05013596A MX PA05013596 A MXPA05013596 A MX PA05013596A
- Authority
- MX
- Mexico
- Prior art keywords
- mch
- antagonists
- obesity
- treatment
- compounds
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 4
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 101800002739 Melanin-concentrating hormone Proteins 0.000 abstract 5
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 abstract 5
- 102000047659 melanin-concentrating hormone Human genes 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010020710 Hyperphagia Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48361903P | 2003-06-30 | 2003-06-30 | |
| PCT/US2004/020763 WO2005005419A1 (en) | 2003-06-30 | 2004-06-28 | Mch antagonists for the treatment of obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05013596A true MXPA05013596A (es) | 2006-03-09 |
Family
ID=34061963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05013596A MXPA05013596A (es) | 2003-06-30 | 2004-06-28 | Antagonistas de hormona concentradora de melanina para el tratamiento de obesidad. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7345042B2 (https=) |
| EP (1) | EP1644366A1 (https=) |
| JP (1) | JP4605801B2 (https=) |
| CN (1) | CN1812985A (https=) |
| CA (1) | CA2526725A1 (https=) |
| MX (1) | MXPA05013596A (https=) |
| WO (1) | WO2005005419A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0509803A (pt) | 2004-04-13 | 2007-09-18 | Incyte Corp | derivados de piperazinilpiperidina como antagonistas de receptor de quimiocina |
| US20080027072A1 (en) * | 2006-04-20 | 2008-01-31 | Ampla Pharmaceuticals, Inc. | Potentiation of MC4 receptor activity |
| US20080108586A1 (en) * | 2006-09-06 | 2008-05-08 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| EP4092013A1 (en) | 2017-06-20 | 2022-11-23 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
| WO2020081361A1 (en) | 2018-10-17 | 2020-04-23 | Imbria Pharmaceuticals, Inc. | Methods of treating rheumatic diseases using trimetazidine-based compounds |
| WO2020243120A1 (en) | 2019-05-31 | 2020-12-03 | Imbria Pharmaceuticals, Inc. | Methods of treating fibrosis using compounds that promote glucose oxidation |
| US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| US5889006A (en) | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| US5908830A (en) | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
| US6391865B1 (en) * | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| CA2371583C (en) | 1999-05-04 | 2005-09-13 | Schering Corporation | Piperazine derivatives useful as ccr5 antagonists |
| JP2004516239A (ja) * | 2000-07-06 | 2004-06-03 | ニューロジェン コーポレイション | メラニン凝集ホルモン受容体リガンド |
| US6900329B2 (en) * | 2001-03-21 | 2005-05-31 | Schering Corporation | MCH antagonists and their use in the treatment of obesity |
| IL158941A0 (en) * | 2001-05-22 | 2004-05-12 | Neurogen Corp | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
| IL161717A0 (en) * | 2001-11-26 | 2004-09-27 | Schering Corp | Piperidine-based mch antagonists for treatment of obesity and cns disorders |
| EP1465888A2 (en) * | 2002-01-10 | 2004-10-13 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues |
| WO2004078717A1 (en) * | 2003-03-03 | 2004-09-16 | Merck & Co., Inc. | Acylated piperazine derivatives as melanocortin-4 receptor agonists |
| EP1633737A1 (en) * | 2003-06-13 | 2006-03-15 | Schering Aktiengesellschaft | Quinolyl amide derivatives as ccr-5 antagonists |
-
2004
- 2004-06-28 MX MXPA05013596A patent/MXPA05013596A/es not_active Application Discontinuation
- 2004-06-28 EP EP04777221A patent/EP1644366A1/en not_active Withdrawn
- 2004-06-28 CN CNA2004800183172A patent/CN1812985A/zh active Pending
- 2004-06-28 JP JP2006517746A patent/JP4605801B2/ja not_active Expired - Fee Related
- 2004-06-28 US US10/878,788 patent/US7345042B2/en not_active Expired - Fee Related
- 2004-06-28 WO PCT/US2004/020763 patent/WO2005005419A1/en not_active Ceased
- 2004-06-28 CA CA002526725A patent/CA2526725A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7345042B2 (en) | 2008-03-18 |
| EP1644366A1 (en) | 2006-04-12 |
| CN1812985A (zh) | 2006-08-02 |
| JP4605801B2 (ja) | 2011-01-05 |
| US20050004121A1 (en) | 2005-01-06 |
| CA2526725A1 (en) | 2005-01-20 |
| JP2007521286A (ja) | 2007-08-02 |
| WO2005005419A1 (en) | 2005-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04003858A (es) | Antagonistas de mch para el tratamiento de obesidad. | |
| MXPA04004956A (es) | Antagonistas de la hormona concentradora de melanina basados en la piperidina para tratamiento de la obesidad y de trastornos del sistema nervioso central. | |
| EA200900658A1 (ru) | Производные индазолилэфиров или -амидов для лечения расстройств, опосредованных глюкокортиодными рецепторами | |
| TW200531689A (en) | Therapeutic agents | |
| MY146972A (en) | Novel compounds as opioid receptor modulators. | |
| MXPA04000707A (es) | Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas. | |
| BR0208150A (pt) | Antagonistas de mch e sua aplicação no tratamento da obesidade | |
| TW200504034A (en) | Therapeutic agents | |
| WO2003028641A3 (en) | Mch receptor antagonists | |
| MXPA05010712A (es) | Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias. | |
| TW200635903A (en) | Therapeutic agents | |
| PT1716152E (pt) | Compostos heterocíclicos fundidos e sua utilização como antagonistas do receptor metabotrópico para o tratamento de distúrbios gastrointestinais | |
| SE0403006D0 (sv) | New compounds | |
| TW200611695A (en) | Pyrrolopyridine derivatives | |
| EP1398029A8 (en) | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives | |
| TW200720260A (en) | Prokineticin 1 receptor antagonists | |
| MY139454A (en) | 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists | |
| TW200716566A (en) | Prokineticin 2 receptor antagonists | |
| PT1725536E (pt) | Derivados de imidazolina apresentando actividade antagonista cb1 | |
| MXPA05013596A (es) | Antagonistas de hormona concentradora de melanina para el tratamiento de obesidad. | |
| MXPA05009193A (es) | Biariltetrahidroisoquinolina piperidinas como antagonistas receptores selectivos de la hormona que concentra la melanina para el tratamiento de la obesidad y trastornos relacionados. | |
| IS8377A (is) | Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns | |
| NO20050270L (no) | Nye forbindelser, deres anvendelse og fremstilling | |
| MXPA06000269A (es) | Tiofenilaminoimidazolinas. | |
| PL1745010T3 (pl) | Podstawione pochodne cykloheksylo-1,4-diaminy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |